Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Biogen Japan Chief Hopes to Build Momentum in ALS Space Riding on Success with Qalsody
Biogen Japan President Takatsugu Den said on December 27 that he hopes that the Japanese approval of the company’s amyotrophic lateral sclerosis (ALS) drug Qalsody (tofersen) will give fresh impetus to ongoing R&D efforts targeting this fatal neurodegenerative disease. “I…
To read the full story
Related Article
- Japan Approves Zepbound, Qalsody, and Lots More Drugs
December 27, 2024
BUSINESS
- FunPep Allergy Vaccine Misses Exploratory Efficacy Goals in PI
July 29, 2026
- Takeda Files Entyvio IV for Pediatric Use, New Adult Dosing in Japan
July 29, 2026
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…